Skip to main content
Premium Trial:

Request an Annual Quote

Gerald Herman

Bruker has appointed Gerald Herman as interim CFO effective March 17. Herman was also recently appointed as principal accounting officer for the company, and he will assume his additional responsibilities as interim CFO following the departure of current CFO Anthony Mattacchione, whose resignation was announced in February. Herman joined the company in 2016 as vice president and corporate controller. Prior to that, he held senior executive positions with various publicly traded companies including Parexel International and Presstek.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.